CHC

MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis.

Leave a Comment / CHC / By

Vitellius C, Desjonqueres E, Lequoy M, Amaddeo G, Fouchard I, N’Kontchou G, Canivet CM, Ziol M, Regnault H, Lannes A, Oberti F, Boursier J, Ganne-Carrie N.JHEP Rep. 2024 Jun 29;6(10):101160. doi: 10.1016/j.jhepr.2024.101160. eCollection 2024 Oct.PMID: 39411648  Abstract Background & aims: Despite its growing incidence, hepatocellular carcinoma (HCC) related to metabolic dysfunction-associated steatotic liver disease (MASLD) in non-cirrhotic livers …

MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis. Read More »

EASL position paper on clinical follow-up after HCV cure.

Leave a Comment / CHC, Cirrhose / By

Reiberger T, Lens S, Cabibbo G, Nahon P, Zignego AL, Deterding K, Elsharkawy AM, Forns X.J Hepatol. 2024 Aug;81(2):326-344. doi: 10.1016/j.jhep.2024.04.007. Epub 2024 Jun 6.PMID: 38845253 Review. Abstract Following the advent of direct-acting antivirals (DAAs), hepatitis C virus (HCV) infection can be cured in almost all infected patients. This has led to a number of clinical questions regarding …

EASL position paper on clinical follow-up after HCV cure. Read More »

Upfront multi-bipolar radiofrequency ablation for HCC in transplant-eligible cirrhotic patients with salvage transplantation in case of recurrence.

Leave a Comment / CHC / By

Boros C, Sutter O, Cauchy F, Ganne-Carrié N, Nahon P, N’kontchou G, Ziol M, Grando V, Demory A, Blaise L, Dondero F, Durand F, Soubrane O, Lesurtel M, Laurent A, Seror O, Nault JC.Liver Int. 2024 Jun;44(6):1464-1473. doi: 10.1111/liv.15900. Epub 2024 Apr 6.PMID: 38581233 Abstract Introduction: We aim to assess the long-term outcomes of percutaneous multi-bipolar radiofrequency (mbpRFA) …

Upfront multi-bipolar radiofrequency ablation for HCC in transplant-eligible cirrhotic patients with salvage transplantation in case of recurrence. Read More »

Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.

Leave a Comment / CHC / By

Campani C, Imbeaud S, Couchy G, Ziol M, Hirsch TZ, Rebouissou S, Noblet B, Nahon P, Hormigos K, Sidali S, Seror O, Taly V, Ganne Carrie N, Laurent-Puig P, Zucman-Rossi J, Nault JC.Gut. 2024 Oct 7;73(11):1870-1882. doi: 10.1136/gutjnl-2024-331956.PMID: 39054058 Abstract Objective: Circulating tumour DNA (ctDNA) is a promising non-invasive biomarker in cancer. We aim to assess the dynamic …

Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments. Read More »

Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab

CHC / By

Limousin W, Laurent-Puig P, Ziol M, Ganne-Carrié N, Nahon P, Ait-Omar A, Seror O, Sidali S, Campani C, Blanc P, Lermine A, Marisa L, Zucman-Rossi J, Nault JC.J Hepatol. 2023 Dec;79(6):1450-1458. doi: 10.1016/j.jhep.2023.08.017. Epub 2023 Aug 28.PMID: 37647991 Background & aims: The “French Medicine Genomic program 2025” has been designed to give patients with cancers …

Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab Read More »

Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis

CHC / By

Nahon P, Bamba-Funck J, Layese R, Trépo E, Zucman-Rossi J, Cagnot C, Ganne-Carrié N, Chaffaut C, Guyot E, Ziol M, Sutton A, Audureau E; ANRS CO12 CirVir and CIRRAL groups. J Hepatol. 2023 Mar;78(3):584-595. doi: 10.1016/j.jhep.2022.11.003. Background & aims: Identifying individuals at higher risk of developing hepatocellular carcinoma (HCC) is pivotal to improve the performance …

Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis Read More »

The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during surveillance of patients with cirrhosis

CHC, Cirrhose / By

Nahon P, Layese R, Ganne-Carrié N, Moins C, N’Kontchou G, Chaffaut C, Ronot M, Audureau E, Durand-Zaleski I, Natella PA; ANRS CO12 CirVir and CIRRAL groups. Hepatology. 2023 Sep 29. doi: 10.1097/HEP.0000000000000615. Background and aims: Hepatocellular carcinoma (HCC) surveillance is challenged by the detection of hepatic focal lesions (HFLs) of other types. This study aimed …

The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during surveillance of patients with cirrhosis Read More »

Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab

CHC / By

Campani C, Bamba-Funck J, Campion B, Sidali S, Blaise L, Ganne-Carrié N, Demory A, Sutter O, Larrey E, Evain M, Ghannouchi H, Wagner M, Marra F, Sutton A, Allaire M, Nault JC. Liver Int. 2023 Mar;43(3):708-717. doi: 10.1111/liv.15487. Epub 2022 Dec 14. Background: The combination of atezolizumab and bevacizumab (AtezoBev) is the current first-line treatment …

Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab Read More »

Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002-2022)

CHC / By

Sidali S, Sritharan N, Campani C, Gregory J, Durand F, Ganne-Carrié N, Ronot M, Lévy V, Nault JC. JHEP Rep. 2023 Apr 7;5(7):100755. doi: 10.1016/j.jhepr.2023.100755. Background & aims: The fragility index (FI), i.e., theminimum number of best survivors reassigned to the control group required to revert the statistically significant result of a clinical trial to …

Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002-2022) Read More »

HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis

CHC / By

Singal AG, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y, Yang JD, Reig M, Cabibbo G, Nahon P, Parikh ND, Marrero JA. Abstract Background & aims: There is controversy regarding the overall value of hepatocellular carcinoma (HCC) surveillance in patients with cirrhosis given the lack of data from randomized-controlled trials. To address this issue, we …

HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis Read More »